SAB BIOTHERAPEUTICS, INC. (SABS) Total liabilities 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABS) total liabilities at each fiscal year-end, per SEC filings.
$21.3MFY2025 · since FY2020: $17.5M → $21.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $21.3M | +16.9% |
| FY2024 | $18.2M | -31.6% |
| FY2023 | $26.6M | +34.2% |
| FY2022 | $19.8M | -53.4% |
| FY2021 | $42.6M | +143.0% |
| FY2020 | $17.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SABS financial trends
SABS RevenueSABS Net incomeSABS Net marginSABS Gross profitSABS Gross marginSABS Operating incomeSABS Operating marginSABS Operating cash flowSABS Free cash flowSABS Capital expendituresSABS Return on equitySABS Stock buybacksSABS Dividends paidSABS Total assetsSABS Shareholders’ equitySABS overview →